Applied DNA Sciences Begins a Testing Program for Novel Anti-Sepsis Agents for Accuthera, Inc.
July 27 2006 - 6:00AM
PR Newswire (US)
STONY BROOK, N.Y., July 27 /PRNewswire-FirstCall/ -- Applied DNA
Sciences, Inc. (OTC:APDN) (BULLETIN BOARD: APDN) , a DNA security
solutions company, today announced that it has agreed to a
commercial agreement providing for APDN to manage a portion of a
testing program for Accuthera, Inc, focusing on evaluation of a
novel series of proteinase inhibitors. The Accuthera program is
being conducted in conjunction with an ongoing major initiative of
the Rocky Mountain Regional Center of Excellence in Fort Collins,
CO, under the sponsorship of the National Institute of Allergy and
Infectious Diseases. Accuthera is pursuing the development of a
novel series of low molecular weight compounds for controlling the
systemic inflammation associated with sepsis. This condition is
associated with high morbidity and mortality. Previous efforts to
develop successful targeted therapeutic strategies for sepsis have
been limited by incomplete understanding of the requirements for
optimal drug design as well as inadequate detection of early
warning signs of escalating systemic inflammatory responses in
septic patients. If these warning signs could be recognized with
greater reliability, the effectiveness of therapeutic interventions
could be considerably increased. Accuthera's approach makes use of
rigorous evaluation of biomarkers under conditions amenable to
monitoring in the hospital bedside setting as well as comprehensive
evaluation of the functional efficacy of its candidate proteinase
inhibitors under conditions replicating the onset of the systemic
inflammatory response. Dr. John C. Cheronis, M.D., Ph.D, CEO of
Accuthera Inc., stated, "We are very pleased to develop a
collaboration with Applied DNA Sciences. The results from the tests
to be funded by us and managed by Applied DNA will help us screen
candidate drugs for efficacy using a number of in vitro assays."
Dr. James A. Hayward, Ph.D., Sc.D., CEO of APDN, stated, "The
current management team at Applied has extensive previous
experience with the development and commercialization of proteinase
inhibitors. In addition, our decision to join this partnership is
to also designed to facilitate collaboration between Accuthera and
investigators at Stony Brook University. APDN is seeking to
increase its presence in the pharma and biotech industries, where
the scientific foundations of APDN's platforms can be applied to
prevent the production and distribution of counterfeit drugs."
About Applied DNA Sciences, Inc. Applied DNA Sciences, Inc. (APDN)
develops proprietary DNA-embedded security solutions that use plant
DNA to verify authenticity and protect corporate and government
agencies from counterfeiting, fraud, piracy, product diversion,
identity theft and unauthorized intrusion into physical plant and
databases. Our common stock is registered under Section 12(g) of
the Securities Exchange Act of 1934 and is listed on the
Over-The-Counter Bulletin Board under the symbol "APDN". Contact:
MeiLin Wan, Applied DNA Sciences, Inc., 25 Health Sciences Drive,
Stony Brook, New York 11790; Tel: 631-444-6370; Fax: 631-444.8848
http://www.adnas.com/. The statements made by Applied DNA Sciences,
Inc. may be forward-looking in nature and are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. Forward-looking statements describe the Company's
future plans, projections, strategies and expectations, and are
based on assumptions and involve a number of risks and
uncertainties, many of which are beyond the control of Applied DNA
Sciences, Inc. Actual results could differ materially from those
projected due to changes in interest rates, market competition,
changes in the local and national economies, and various other
factors detailed from time to time in Applied DNA Sciences' SEC
reports and filings, including our Annual Report on Form 10-KSB,
filed on January 12, 2006, our subsequent Quarterly Reports on Form
10-QSB, and our Current Reports on Form 8-K. The Company undertakes
no obligation to update publicly any forward-looking statements to
reflect new information, events or circumstances after the date
hereof to reflect the occurrence of unanticipated events.
DATASOURCE: Applied DNA Sciences, Inc. CONTACT: MeiLin Wan of
Applied DNA Sciences, Inc., +1-631-444-6370, fax: +1-631-444-8848
Web site: http://www.adnas.com/
Copyright